Tango Therapeutics, Inc. (TNGX) Free cash flow 2020–2025
Tango Therapeutics, Inc. (TNGX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$139.9MFY2025 · since FY2020: $69.0M → -$139.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$139.9M | -5.8% |
| FY2024 | -$132.3M | -10.7% |
| FY2023 | -$119.5M | -2.3% |
| FY2022 | -$116.8M | -90.3% |
| FY2021 | -$61.4M | -189.0% |
| FY2020 | $69.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TNGX financial trends
TNGX RevenueTNGX Net incomeTNGX Net marginTNGX Gross profitTNGX Gross marginTNGX Operating incomeTNGX Operating marginTNGX Operating cash flowTNGX Capital expendituresTNGX Return on equityTNGX Stock buybacksTNGX Dividends paidTNGX Total assetsTNGX Total liabilitiesTNGX Shareholders’ equityTNGX overview →